 SEATTLE, May 05, 2022 GLOBE NEWSWIRE -- Neoleukin Therapeutics, Inc., Neoleukin NASDAQ:NLTX, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in two upcoming investor conferences. Presentation details are as follows: 